ABBV logo AbbVie +
AbbVie
+

AbbVie (ABBV) Business News

Track AbbVie in real time with a live news feed covering AbbVie stock news, official press releases, company announcements, and an archive of historical AbbVie news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:05 AM | Thursday | Oct 8, 2026 ETF Trends

AI ETFs: Beyond Chips & Hyperscalers

NEW News Thumbnail
10:15 AM | Wednesday | Oct 7, 2026 24/7 Wall Street

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

News Thumbnail
8:30 AM | Wednesday | Oct 7, 2026 PRNewsWire

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

News Thumbnail
10:15 AM | Wednesday | Oct 7, 2026 24/7 Wall Street

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

News Thumbnail
8:30 AM | Wednesday | Oct 7, 2026 PRNewsWire

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

News Thumbnail
12:26 PM | Tuesday | Oct 6, 2026 Zacks Investment Research

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

News Thumbnail
10:31 AM | Tuesday | Oct 6, 2026 Zacks Investment Research

Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?

News Thumbnail
9:50 AM | Tuesday | Oct 6, 2026 The Motley Fool

Should You Buy AbbVie Stock Before Oct. 30?

News Thumbnail
8:49 AM | Tuesday | Oct 6, 2026 247 Wallst

$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely

News Thumbnail
8:25 AM | Tuesday | Oct 6, 2026 24/7 Wall Street

AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News

News Thumbnail
8:12 AM | Tuesday | Oct 6, 2026 Defense World

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

News Thumbnail
7:26 AM | Tuesday | Oct 6, 2026 Defense World

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

News Thumbnail
7:38 AM | Monday | Oct 5, 2026 Defense World

AbbVie Inc. $ABBV Stock Position Lessened by MassMutual Private Wealth & Trust FSB

News Thumbnail

AI ETFs: Beyond Chips & Hyperscalers

ETF Trends

7:05 AM | Thursday | Oct 8, 2026

news photo
Loading...

While AI investing initially centered on hyperscalers and chips, the opportunity has been broadening as infrastructure grows. Opportunities are moving further down and across the supply chain — into memory, data center power, components, and robotics.

Read full article redirect
7:05 AM | Thursday | Oct 8, 2026

AI ETFs: Beyond Chips & Hyperscalers

ETF Trends

While AI investing initially centered on hyperscalers and chips, the opportunity has been broadening as infrastructure grows. Opportunities are moving further down and across the supply chain — into memory, data center power, components, and robotics.

Read full article arrow
NEW News Thumbnail
10:15 AM | Wednesday | Oct 7, 2026

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

24/7 Wall Street

A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Oct 7, 2026

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

PRNewsWire

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) These designations represent the first Breakthrough Therapy Designations (BTDs) for Temab-A and further underscore the strength of AbbVie's ADC portfolio, which now includes four BTDs NORTH CHICAGO, Ill., Oct. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).

Read full article arrow
News Thumbnail
10:15 AM | Wednesday | Oct 7, 2026

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

24/7 Wall Street

A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Oct 7, 2026

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

PRNewsWire

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) These designations represent the first Breakthrough Therapy Designations (BTDs) for Temab-A and further underscore the strength of AbbVie's ADC portfolio, which now includes four BTDs NORTH CHICAGO, Ill., Oct. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).

Read full article arrow
News Thumbnail
12:26 PM | Tuesday | Oct 6, 2026

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

Zacks Investment Research

ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.

Read full article arrow
News Thumbnail
10:31 AM | Tuesday | Oct 6, 2026

Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?

Zacks Investment Research

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read full article arrow
News Thumbnail
9:50 AM | Tuesday | Oct 6, 2026

Should You Buy AbbVie Stock Before Oct. 30?

The Motley Fool

AbbVie has generated solid double-digit growth in its most recent quarters. Additional approvals for its top drugs could lead to more growth.

Read full article arrow
News Thumbnail
8:49 AM | Tuesday | Oct 6, 2026

$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely

247 Wallst

When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible moment. Five companies have raised their dividends through every recession and rate shock in modern memory, and together they turn a single portfolio into a reliable cash machine.

Read full article arrow
News Thumbnail
8:25 AM | Tuesday | Oct 6, 2026

AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News

24/7 Wall Street

AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.

Read full article arrow
News Thumbnail
8:12 AM | Tuesday | Oct 6, 2026

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

Defense World

AbbVie (NYSE: ABBV - Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.730-3.770 for the period, compared to the consensus EPS estimate of 3.850.
The company issued revenue guidance of -. Wall Street Analyst Weigh In A number of equities research

Read full article arrow
News Thumbnail
7:26 AM | Tuesday | Oct 6, 2026

AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance

Defense World

AbbVie (NYSE: ABBV - Get Free Report) updated its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.730-3.770 for the period, compared to the consensus estimate of 3.850.
The company issued revenue guidance of -. Analysts Set New Price Targets A number of research firms have recently

Read full article arrow
News Thumbnail
7:38 AM | Monday | Oct 5, 2026

AbbVie Inc. $ABBV Stock Position Lessened by MassMutual Private Wealth & Trust FSB

Defense World

MassMutual Private Wealth and Trust FSB decreased its holdings in AbbVie Inc. (NYSE: ABBV) by 5.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 155,837 shares of the company's stock after selling 8,510 shares during the quarter.

Read full article arrow
News Thumbnail